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Abstract
Background: Troglitazone (TGZ) is a potential anticancer agent. Little is known about the effect
of this agent on cancer cell migration.
Methods: Human ovarian carcinoma cell line, ES-2 cells were treated with various concentrations
of TGZ. Cell migration was evaluated by wound-healing and Boyden chamber transwell
experiments. PPARγ expression was blocked by PPARγ small interfering RNA. The effects of TGZ
on phosphorylation of FAK, PTEN, Akt were assessed by immunoblotting using phospho-specific
antibodies. The cellular distribution of paxillin, vinculin, stress fiber and PTEN was assessed by
immunocytochemistry.
Results: TGZ dose- and time-dependently impaired cell migration through a PPARγ independent
manner. TGZ treatment impaired cell spreading, stress fiber formation, tyrosine phosphorylation
of focal adhesion kinase (FAK), and focal adhesion assembly in cells grown on fibronectin
substratum. TGZ also dose- and time-dependently suppressed FAK autophosphorylation and
phosphorylation of the C-terminal of PTEN (a phosphatase). At concentration higher than 10 µM,
TGZ caused accumulation of PTEN in plasma membrane, a sign of PTEN activation.
Conclusion: These results indicate that TGZ can suppress cultured ES-2 cells migration. Our data
suggest that the anti-migration potential of TGZ involves in regulations of FAK and PTEN activity.
Background
Ovarian carcinoma is a leading cause of gynecologic can-
cer death [1]. The tumor spread into the peritoneal cavity
is a hard-to-treat and frequent occurrence [2]. Morbidity
and mortality rates due to disseminated ovarian carci-
noma remain high [3,4]. Thus agents capable of prevent-
ing ovarian carcinoma metastasis may be of great
therapeutic value.
Cancer metastasis involves cell proliferation, detachment
of cells from extracellular matrix, invasion across base-
ment membrane and vessel walls, and migration within
Published: 20 November 2007
BMC Cancer 2007, 7:216 doi:10.1186/1471-2407-7-216
Received: 24 July 2007
Accepted: 20 November 2007
This article is available from: http://www.biomedcentral.com/1471-2407/7/216
© 2007 Yang et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2007, 7:216 http://www.biomedcentral.com/1471-2407/7/216
Page 2 of 12
(page number not for citation purposes)
extracellular matrix (ECM). Our current understanding of
cell migration comes mainly from study of monolayer
cultures of cancer cells. Cells attach to culture surface by
forming focal adhesions (FAs) where ECM and integrins-
associated membrane interact [5,6]. Cell migration
involves assembly and disassembly of FAs and is stimu-
lated extracellularly and initiated by intracellular signal-
ing proteins located in FAs [5,6]. Focal adhesion kinase
(FAK) is a non-receptor protein tyrosine kinase that is acti-
vated mainly in FAs and important in cell-ECM interac-
tions that affect cell migration, proliferation, and survival
[5-9]. Evidence indicates that overexpression of FAK is
correlated with tumor progression and that FAK is signifi-
cantly overexpressed in ovarian carcinoma [6,10,11]. Fur-
thermore, immunohistochemical analysis of ovarian
cancer samples reveals that enhanced FAK expression is
correlated with ovarian carcinoma dissemination and
poor prognosis [11].
The key event in FAK activation is autophosphorylation of
Tyr397 [12]. It has been proposed that integrin clustering
induced by cell spreading on matrix proteins promotes
FAK autophosphorylation [9]. Autophosphorylation of
FAK provides a binding site for Src family kinases that
renders FAK phosphorylated at several other sites and
leads to enhanced FAK activation [12,13]. Evidence indi-
cates that FAK autophosphorylation promotes focal-com-
plex assembly, and that many signaling and structural
proteins such as Src kinases, vinculin, paxillin, and F-actin
are recruited by the focal complex [5]. On the other hand,
activated FAK can serve as an efficient scaffold protein for
delivery of crucial molecules (such as calpain-2) to focal-
adhesion sites that cause disassembly of FAs [5,14]. There-
fore, FAK is a key molecule for controlling cell migration
owing to its involvement in the regulation of FA turnover
[5,6]. Growing evidence indicates that autophosphor-
ylated FAK (pY397FAK) is increased in various types of
tumor [15-17]. Also, pY397FAK was found in invasive
ovarian carcinomas, but not in normal ovarian epithe-
lium [18]. The in vitro invasiveness, spread, and migratory
abilities of ovarian cancer cell lines are decreased by the
introduction of the dominant-negative construct of FAK
[11]. These observations suggest that inhibition of FAK
activation might be an anti-cancer mechanism [6].
Peroxisome proliferator-activated receptor gamma
(PPARγ) is a ligand-activated transcriptional factor and a
member of the nuclear hormone receptor superfamily
[19]. A number of PPARγ ligands have been identified.
Examples include natural prostaglandins, such as 15-
deoxy-∆12,14-PGJ2 (15d-PGJ2), and synthetic antidiabetic
thiazolidinediones (TZDs), such as troglitazone (TGZ)
and ciglitazone (CGZ) [20,21]. TZDs are widely used as
antihyperglycemic agents [22]. PPARγ ligands may have
potential as anticancer agents [23,24]. TZDs are known to
act by inducing mitotic arrest and apoptosis in most can-
cer cells. Cell apoptosis induced by PPARγ ligands is usu-
ally accompanied by cell detachment from the culture
substratum [25,26]. The effect of PPARγ ligands on focal
adhesions (FAs) assembly has been examined.
PPARγ ligands induce focal adhesion disassembly and
decrease in FAK phosphorylation, which may be involved
in induction of apoptosis [25,27]. On the other hand,
PPARγ ligands has been proposed to inhibit cell motility
through its effect on actin organization [28], increase of c-
myc expression [29] and inhibition of angiogenesis [30].
In addition, recent reports indicate that PPARγ ligands can
reduce human pancreatic cancer cells and myeloid leuke-
mia cells invasion through modulation of the plasmino-
gen activator system or activities of matrix
metalloproteinases [28,31-33]. Although these studies
imply that PPARγ ligands have potential as anti-metastatic
agents, their effects on cancer cell migration remain unin-
vestigated.
PTEN (phosphatase and tensin homologue deleted on
chromosome ten), an identified tumor suppressor, is also
involved in the regulation of cell migration [34-37]. Its
proposed function involves modulation of FAK phospho-
rylation [36,37]. Recent study revealed complex regula-
tion of activity of PTEN. The membrane-binding and
activation mechanism of PTEN is determined by phos-
phorylation of its C-terminal tail, and C-terminal phos-
phorylation suppresses PTEN membrane recruitment [38-
40]. Dephosphorylation of PTEN promotes its transfer to
the cell membrane and induces its phosphatase activity to
suppress growth factor-mediated Akt survival signaling, or
interact with phosphorylated FAK to dephosphorylate
FAK [36,37,41]. Interestingly, recent studies found that
PPARγ ligands can upregulate PTEN expression by
enhancing PPARγ transcriptional activity in several types
of tumor cell lines [42-44]. However, the influences of
PPARγ ligands on ovarian carcinoma of PTEN expression
and activity remain unclear.
Cell migration is an important process of metastasis. The
effect of PPARγ ligands on local motility, their potential
effect on FAs formation, and their anticancer effect on
ovarian cancer cells is unclear and not well studied. There-
fore, the purpose of this study was to clarify the effect of
TGZ on the cell motility of a human ovarian cancer cell
line.
Methods
Cell culture
Human ovarian carcinoma cell line, ES-2, was obtained
from the American Type Culture Collection (ATCC; Rock-
ville, MD, USA) and grown in McCoy's 5A medium with
10% FBS.BMC Cancer 2007, 7:216 http://www.biomedcentral.com/1471-2407/7/216
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Wound healing assay
Cells (1 × 106) were plated on 6-well culture plates (Corn-
ing, Corning, NY, USA) in 10% FBS-containing medium.
Upon confluence, the cell layer was scratched with a P-
200 pipette tip. The cells were then cultivated in complete
medium in the presence or absence of TGZ (Calbiochem,
La Jolla, CA, USA). Photographs of the wound adjacent to
reference lines scraped on the bottom of the plate were
taken using a Nikon ECLIPSE TS100 microscope (under
20× field) at various time points and then counted the
number of migrated cells from these photographs.
Transwell chamber migration assay
The assays were conducted using 8.0-µm pore size and 6.5
mm diameter transwell filters (Costar, Cambridge, MA,
USA). The undersurface of the polycarbonate membrane
of the chambers was coated with FN (10 µg/ml in PBS; 2
h at 37°C). The membrane was washed in PBS to remove
excess ligand, and the lower chamber was filled with 500
µL of 10% FBS-containing medium. ES-2 cells were har-
vested using limited trypsin treatment by washed twice in
medium containing 0.5 mg/ml soybean trypsin inhibitor
(Sigma, St. Louis, MO, USA) and once in serum-free
medium. Cells (1 × 105 per chamber) were resuspended in
0.2 ml of serum-free medium and added to the upper
chamber for 1 h then treated with TGZ at the concentra-
tions indicated in the text. After 5 h at 37°C in 5% CO2,
cells were fixed with 4% paraformaldehyde for 15 min at
RT, and stained with 0.1 mg/mL crystal violet solution.
The cells on the upper surface of the membrane were
removed using cotton buds. The number of migrated cells
on the underside of the membrane was counted micro-
scopically using a 20× objective (cells/mm2).
Cell spreading assay
ES-2 cells were harvested using limited trypsin treatment
as described (above) under Transwell Chamber Migration
Assay. Cells (3 × 105 per 12-well chamber) were resus-
pended in complete medium with or without 20 µM TGZ
for 1 h on human FN-coated coverslips. The mean size of
the cells was quantified by analyzing 100 cells from ran-
domly selected fields using MetaMorph software (Univer-
sal Imaging, Downingtown, PA, USA).
Immunocytochemistry
ES-2 cells were harvested using limited trypsin treatment
as described (above) under Transwell Chamber Migration
Assay. Cells were plated on human FN-coated coverslips
in complete medium contained DMSO or 20 µM TGZ for
4 h or 24 h, fixed with 4% paraformaldehyde (20 min),
permeabilized by 0.5% Triton X-100 in PBS (20 min), and
blocked with 1% bovine serum albumin (1 h). Cells were
incubated with monoclonal antibodies to paxillin (1:200
dilution; BD Transduction Labs, Lexington, KY, USA), vin-
culin (1:200; Chemicon, Temecula, CA, USA), or PTEN
(1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA),
and then with FITC-labeled horse anti-mouse IgG (1:500;
Vector Labs, Burlingame, CA, USA). Cytoskeletal proteins
were visualized by 30 µM rhodamine-phalloidin (Sigma).
After final washes and mounting, cells were examined
using confocal microscopy (LSM410, Carl Zeiss, Oberko-
chen, Germany).
Cell lysis, fractionation, and SDS-PAGE
Following treatment, ES-2 cells were scraped into lysis
buffer (150 µL/35 mm well) containing 20 mM HEPES
(pH 7.4), 1% SDS, 150 mM NaCl, 1 mM EGTA, 5 mM β-
glycerophosphate, 10 mM sodium pyrophosphate, 10
mM sodium fluoride, 100 µM sodium orthovanadate, 10
µg/mL leupeptin, and 10 µg/mL aprotinin. The lysate was
incubated on ice for 15 min. Cell debris was removed by
centrifugation at 12,000 × g for 15 min at 4°C. Membrane
and cytoplasmic proteins from ES-2 cells were extracted
with ProteoExtract® Native Membrane Protein Extraction
Kit (Calbiochem) according to the manufacturer's instruc-
tions. Protein concentration of each sample was assayed
using BCA Protein Assay Reagent according to manufac-
turer's instructions (Pierce Biotechnology, Rockford, IL,
USA). Each cellular fraction was then resolved on a 12%
SDS-polyacrylamide gel electrophoresis (PAGE) and then
electrotransferred to polyvinylidene fluoride (PVDF)
membranes (Immobilon-P; Millipore, Bedford, MA,
USA).
Immunoprecipitation and Western blot analysis
Immunoprecipitation was performed using anti-FAK (4
µg/mL; BD Transduction Laboratories) antibody. Immu-
noprecipitates were resolved by SDS-PAGE, and analyzed
by Western blotting with anti-phospho-tyrosine antibod-
ies (1:1000 dilution; Abcam Ltd, Cambridge, UK) as
described previously [45]. For Western blot analysis, fifty
micrograms of each protein sample was subjected to SDS-
PAGE and electrotransferred to PVDF membranes,
blocked, and then incubated with primary antibody. Pro-
teins of interest were detected using appropriate IgG-HRP
secondary antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and ECL reagent (Amersham, Arlington
Heights, IL, USA). Primary antibodies included phospho-
Tyr-397 FAK (1:1000; Biosource, Camarillo, CA, USA),
FAK (1:1000; BD Transduction Laboratories), PTEN
(phospho S380 + T382 + T383; 1:1000; Abcam Ltd),
PTEN (1:1000; Santa Cruz Biotechnology), PPARγ
(1:1000 dilution, Santa Cruz Biotechnology), Bax
(1:1000, Upstate Biotechnology, Lake Placid, NY, USA),
pS473 Akt (1:1000; Promega, Madison, WI, USA), Akt
(1:1000; Santa Cruz Biotechnology), N-cadherin (1:1000;
Transduction Laboratories), and β-actin (Sigma) and were
used according to the manufacturers' instructions. X-ray
films were scanned on the Model GS-700 Imaging Densi-BMC Cancer 2007, 7:216 http://www.biomedcentral.com/1471-2407/7/216
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tometer (Bio-Rad Laboratories, Inc., Hercules, CA, USA)
and analyzed using Labworks 4.0 software.
PPARγ small interfering RNA treatment
The sequences of PPARγ1 siRNA and control pGL3 siRNA
duplexes were synthesized (Dharmacon, Lafayette, CO,
USA) as previously described [46]. For the transfection
procedure, cells were grown to 70% confluence, and
PPARγ siRNA or control siRNA was transfected using Oli-
gofectamine (Invitrogen, Carlsbad, CA, USA). The final
concentration of siRNA was 50 nM. Six hours after siRNA
transfection, cells were resuspended in new culture media,
incubated for additional 16 h, and then treated with TGZ.
Statistical analysis
Data are expressed as mean ± standard deviation (SD) of
three independent experiments, each done in triplicate (n
= 3~4 dishes). The Mann-Whitney U  test was used to
determine statistically significant differences. P values <
0.05 were considered significant.
Results
TGZ dose- and time-dependently inhibits ES-2 cell 
migration
Cells of the ovarian carcinoma cell line, ES-2, were
exposed to increasing concentrations of TGZ (5–30 µM)
in 10% serum-containing medium, and cell migration
was examined using the in vitro wound healing assay. Fig-
ure 1A shows representative photographs of cells migrat-
ing into scratch wounds. The number of cells migrating
into the wound decreased in a TGZ concentration-
dependent manner (Figure 1B). At 20 µM, TGZ decreased
this number 48 ± 2% and 76 ± 3% at 8 h and 24 h, respec-
tively. The decrease did not appear to be due to cytotoxic-
ity since TGZ (5~20 µM) showed no inhibitory effect on
cell proliferation as determined by MTT assay (data not
shown). In addition, CGZ treatment for 24 h also blocked
ES-2 migration, albeit to a lesser degree (Figure 1C com-
pared with 1B).
In an in vitro transwell migration assay, TGZ reduced ES-2
cell migration to the bottom chamber containing fetal
bovine serum (FBS) by ~1.5- and ~2.4-fold at 10 µM and
20 µM, respectively (compared with DMSO treated cells;
P < 0.001, Figure 1D). These results indicate that, at non-
toxic levels, TGZ and CGZ are capable of inhibiting the
migration of ES-2 cells.
TGZ inhibits stress fibers and focal adhesion formation
We next examined the effect of TGZ on focal adhesions
(FAs) formation because its impairment has been shown
to reduce cell migration [6]. After four hours of adhesion
to fibronectin (FN)-coated surfaces, ES-2 cells formed
numerous FAs, which were stained by anti-paxillin. In
cells incubated with 20 µM TGZ, FAs were substantially
reduced (Figure 2A). Similar inhibitory effect of TGZ was
observed when FAs formation was identified by anti-vin-
culin antibody (data not shown). Reduction in the
number of FAs was accompanied by an overall decrease in
actin stress fiber (Figure 2A). It is highly possible that TGZ
treatment decreases the transport or maintenance of
cytoskeletal proteins in FAs, such as paxillin and vinculin,
thereby reducing the number of complexes available for
the formation of strong focal points and actin bundling.
Since tyrosine phosphorylation of FAK (p-FAK) regulates
FAs formation, the level of tyrosine phosphorylation of
FAK after treatment with 20 µM TGZ was investigated.
Western blot analysis revealed a one-half-fold reduction
in p-FAK level after treatment for 4 h and 8 h. The total
level of FAK, however, was not changed (Figure 2B and
2C).
Effects of TGZ on cell spreading
To further assess TGZ inhibition of FA formation, cell
spreading on FN was examined. Within 1 h after seeding,
ES-2 cells, untreated or treated with DMSO, spread well
on FN-coated coverslips. However, treatment with 20 µM
TGZ led to cell retraction from the substratum, loss of con-
tacts between neighboring cells, and eventually in a spin-
dle-shaped morphology (Figure 3, pictures). The rounded
morphology of cells grown on poly-L-lysine (PLL) was not
affected by TGZ treatment (data not shown). Quantitative
morphometric analysis (Materials and Methods) revealed
that TGZ treatment reduced the surface area of spread cells
by twofold (Figure 3, bar graph, P < 0.005). Thus, TGZ
appears to interfere with the molecular events that drive
spreading and the extension of membrane protrusions. In
addition, the effect of TGZ seems to be integrin-depend-
ent since cell spreading on PLL-coated plates was not
affected.
The TGZ-mediated anti-migratory effect is independent of 
the induction of PPARγ expression
Our previous report (Ref. [48]) and this study (Figure 4A)
indicate that TGZ can enhance PPARγ expression in ES-2
cells. To determine whether TGZ-induced PPARγ expres-
sion is required for inhibition of cell migration, ES-2 cells
were transfected with PPARγ-specific siRNA and then
assayed for PPARγ expression and cell migration in the
presence of 20 µM TGZ. Western blotting showed that the
basal level of PPARγ protein was only slightly decreased
by the PPARγ siRNA transfection. However, TGZ-induced
PPARγ expression was significantly reduced by the PPARγ
siRNA and not by the control siRNA (Figure 4A). The tran-
swell cell migration assay revealed the similar capacity of
TGZ to inhibit the migration of both PPARγ siRNA- and
control siRNA-transfected cells (Figure 4B). Therefore,
TGZ-mediated inhibition of ES-2 cell migration is
through a PPARγ-independent mechanism.BMC Cancer 2007, 7:216 http://www.biomedcentral.com/1471-2407/7/216
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TGZ dose- and time-dependently inhibits FAK 
autophosphorylation and PTEN phosphorylation
To investigate whether the FAK autophosphorylation
(pY397FAK) could be affected after TGZ treatment, West-
ern blot analysis was performed and revealed that expo-
sure of cells to varying concentrations of TGZ (10, 20 and
30  µM, 24 h) induced a concentration-dependent
decrease in pY397FAK level (Figure 5A and 5B, P < 0.05 vs.
DMSO-treated cells). Thus, TGZ may inhibit migration by
dose-dependently preventing FAK autophosphorylation.
Accumulating evidence indicates that PTEN inhibits cell
migration, possibly by dephosphorylating p-FAK at Y397
[36,37]. The reduction in pY397FAK level raises the pros-
pect that PTEN is involved in TGZ inhibition of migration.
We thus studied the levels of PTEN and phosphorylated
PTEN in TGZ treated cells and found TGZ (10–30 µM)
reduced PTEN level (~1.8–3.1 fold lower than DMSO-
treated cells; Figure 5A and 5C). Interestingly, the phos-
phorylated PTEN (p-PTEN) level was also dose-depend-
ently decreased (Figure 5A and 5D, P  < 0.05). This
(A and B) TGZ inhibits ES-2 cell migration in a wound healing assay Figure 1
(A and B) TGZ inhibits ES-2 cell migration in a wound healing assay. Cells were wounded and then treated with vehicle 
(DMSO) or TGZ (5–30 µM) for 8 h (grey column) and 24 h (black column) in 10% FBS-containing medium. At 0, 8 and 24 h, 
phase-contrast pictures of the wounds at three different locations were taken and then migrated cells in the wound were 
counted. #P < 0.05 vs. 8 h untreated cells and *P < 0.05 vs. 24 h untreated cells. (C) CGZ inhibits ES-2 cell migration in a wound 
healing assay. Cells were treated with various concentrations of CGZ (5–30 µM) and then the migrated cells were counted 
after treatment for 24 h. *P < 0.05 vs. control. (D) TGZ inhibits migration of ES-2 cells in a transwell assay. ES-2 cells (1 × 105) 
were treated with vehicle (DMSO) or TGZ (10 or 20 µM) for 5 h at 37°C and cell motility was determined as described in 
Materials and Methods. *P < 0.001 vs. DMSO treatment.
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suggests that TGZ treatment induces PTEN degradation
and PTEN dephosphorylation in a dose-dependent way.
To further establish the interaction between PTEN and
pY397FAK, we investigated FAK and PTEN levels at vari-
ous times after TGZ exposure. Western blot analysis indi-
cated that exposure of cells to 20 µM TGZ for 8 h and 24
h caused dramatic decreases in the levels of both
pY397FAK and p-PTEN as compared with untreated- or
DMSO-treated cells (Figure 6). In addition, total PTEN
level was markedly decreased upon TGZ treatment for 8 h
and 24 h. This indicated that TGZ can induce a time-
dependent reduction in pY397FAK, p-PTEN, and PTEN
levels.
TGZ treatment causes plasma membrane accumulation of 
PTEN
Dephosphorylation of the C-terminal of PTEN induces
the lipid phosphatase activity of PTEN which then leads to
accumulation of PTEN on cell membrane [36,37,40]. The
PTEN dephosphorylation not only brings PTEN to its sub-
strate but also leads to the degradation of PTEN itself [47].
The degradation of PTEN after TGZ treatment (shown
above) led us to suspect that PTEN is activated by TGZ. To
confirm this, PTEN accumulation on the cell membrane
was assayed. Cell membrane and cytosolic fractions of
TGZ-treated cells were isolated for Western blot analysis.
As shown in Figure 7A, level of PTEN in the membrane
fraction was not significantly increased in cells treated
with 5 µM and 10 µM TGZ as compared with untreated or
DMSO-treated cells and most PTEN were detected in the
cytosolic fraction. However, at 20 µM and 30 µM, TGZ
triggered PTEN association with the cell membrane and
TGZ inhibits stress fiber and focal adhesion formation Figure 2
TGZ inhibits stress fiber and focal adhesion formation. (A) Effect of TGZ on the distribution of paxillin and stress fib-
ers. ES-2 cells were plated on FN (10 µg/mL)-coated coverslips and incubated in 10% FBS medium with 0.1% DMSO or 20 µM 
TGZ for 4 h. Cells were then double stained with rhodamine-labeled phalloidin and antibodies to paxillin (FITC). These results 
are representative of triplicate experiments. (B) Time-course study of the tyrosine phosphorylation level of focal adhesion 
kinase (FAK) in TGZ-treated ES-2 cells. ES-2 cells were treated with 20 µM TGZ for different intervals. The cell homogenates 
were immunoprecipitated from 1 mg of total cellular protein by anti-FAK antibody and subjected to Western blot analysis with 
anti-phosphotyrosine antibody (p-FAK) or anti-FAK antibody (FAK). The cell homogenates were also analyzed for β-actin lev-
els by Western blotting as indicated. Immunoblot results are from a representative experiment performed in triplicate with β-
actin as loading control. Symbol (*) indicates cells that were treated with DMSO for 8 h.
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PTEN was barely detected in the cytosolic fraction. N-cad-
herin and Bax were used as respective markers of cell
membrane protein and non-membrane protein. Thus,
PTEN membrane translocation is induced by high con-
centration of TGZ.
To further confirm that cell membrane accumulation of
PTEN can be induced by high concentration of TGZ,
immunofluorescence analysis of PTEN localization was
performed. As shown in Figure 7B, in control cells, PTEN
protein was in cytoplasm and cell membrane and had a
similar distribution to paxillin. However, after treatment
with 20 µM TGZ for 24 h, membrane accumulation of
PTEN protein increased, suggesting that the higher con-
centration causes cell membrane accumulation of PTEN,
which is a sign of PTEN activation. This supports the
notion that TGZ induces FAK dephosphorylation by acti-
vating PTEN.
Translocation of activated PTEN to the cell membrane
leads to the dephosphorylation of Akt [41]. Since TGZ
treatment leads to membrane accumulation of PTEN, it
was of interest to document the activation of PTEN by
TGZ. Levels of Akt phosphorylation (p-Akt) were moder-
ately decreased ~2–3-fold in TGZ (20 and 30 µM) treated
TGZ inhibition of cell spreading Figure 3
TGZ inhibition of cell spreading. ES-2 cells treated with 
DMSO or 20 µM TGZ were plated on coverslips which were 
coated with FN (10 µg/ml) or poly-L-lysine (25 µg/ml, PLL). 
The cell surface area after 1 h was determined using Meta-
Morph software  on at least 100 cells from five different 
fields (100 × magnification); n = 3 experiments. *P < 0.005 
versus control. Right panels represent phase-contrast photo-
graphs of ES-2 cells treated with DMSO or TGZ for 1 h.
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cells as compared to TGZ (5 and 10 µM) or DMSO-treated
cells; while total Akt level remained unchanged (Figure
7A). This suggests that the PTEN accumulated on cell
membrane is activated, or at least its ability to inhibit
phosphorylation of Akt is functional. It is plausible to
assume that activated PTEN is also responsible for the
dephosphorylation of pY397FAK.
Discussion
We recently showed that PPARγ agonists (TGZ and CGZ;
1–50 µM) dose-dependently induced growth arrest and
inhibited the viability of ES-2 cells after long-term (48–72
h) treatment [48]. Here we further provide in vitro evi-
dence for additional antitumor properties of TGZ by
showing its potential effect on cell spreading and migra-
tion. We found that TGZ time- and dose-dependently
inhibits 1) cell migration before cell growth and cell via-
bility and 2) FAK autophosphorylation, which correlates
with inhibition of cell migration. In addition, we found
that TGZ treatment at higher concentrations (20 and 30
µM) caused cell membrane accumulation of PTEN, sug-
gesting the involvement of PTEN in TGZ's inhibitory
effect on FAK activation and cell migration. Our data sug-
gest that TGZ may possess anti-metastatic in addition to
anti-proliferation effects.
In the scratch wound-healing assay, the ES-2 cell line
(compared with certain other ovarian carcinoma cell
lines) has a higher degree of motility, suggesting it can be
a suitable model system to study cell migration in vitro
Dose study of the effect of TGZ on the phosphorylation and expression of FAK and PTEN Figure 5
Dose study of the effect of TGZ on the phosphorylation and expression of FAK and PTEN. ES-2 cells were treated 
with different doses of TGZ for 24 h (A). The cell homogenates were subjected to Western blot analysis with various antibod-
ies as indicated. Immunoblot results are from a representative experiment performed in triplicate with β-actin as loading con-
trol. (B) After densitometric scans of triplicate blots, values for pY397FAK were normalized to total FAK. (C and D) Values for 
p-PTEN and PTEN were normalized to β-actin. *P < 0.05 vs. DMSO-treated cells.
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[49]. In the present study, we used the scratch wound-
healing assay to show TGZ (5–30 µM) can impair ES-2 cell
migration in a time- and dose-dependent manner (Figure
1A and 1B). Previous reports that antibodies against
fibronectin (FN) can partially inhibit ovarian carcinoma
cell motility and reduce intraperitoneal spread imply that
the interaction of substratum FN with cell integrins is a
determinant of migration of ovarian carcinoma cells [50-
52]. Our results further clarified TGZ's anti-migratory
effect on ES-2 cells grown on FN substratum by showing
that spreading (Figure 3), F-actin/FAs formation (Figure
2A), and transwell chamber migration (Figure 1D) were
all markedly inhibited by TGZ treatment. Such findings
suggest that TGZ might have anti-migratory activity
against ovarian carcinoma cells.
Although thiazolidinedione ligands (TZDs) were initially
identified as ligands of PPARγ, accumulating evidence
indicates that TGZ can affect cell function independent of
PPARγ receptor activation. Previously, TGZ was shown to
induce cancer cell apoptosis by non-PPARγ mechanisms
[21,53]. In our study, both PPARγ-specific siRNA (Figure
4) and a selective PPARγ antagonist, GW9662 pretreat-
ment (10~20 µM, 2 h; our unpublished data) failed to
reverse the inhibition of migration, indicating for the first
time that TGZ inhibits migration through a PPARγ-inde-
pendent mechanism.
In vitro studies reveal that FAK kinase activity is essential
for cell migration [5,6]. Moreover, the pY397FAK localiza-
tion assayed by immunohistochemistry is detected only in
invasive ovarian carcinomas but not normal ovarian tis-
sue specimens [18]. FAK activation is initiated by auto-
phosphorylation at Tyr 397 (pY397FAK) [12]. Our results
reveal that TGZ dosages required to inhibit cell migration
(Figure 1B and 1D) are the same as those required to
decrease pY397FAK level (Figure 5B), suggesting
pY397FAK may be a potential therapeutic target for treat-
ing ovarian carcinoma metastasis. Interestingly, ES-2 cells
treated with 20 µM TGZ for 4–8 h caused ~50% reduction
Time-course study of the effect of TGZ on the phosphorylation and expression of FAK and PTEN Figure 6
Time-course study of the effect of TGZ on the phosphorylation and expression of FAK and PTEN. ES-2 cells 
were treated with 20 µM TGZ for the time intervals indicated. The cell homogenates were subjected to Western blot analysis 
with various antibodies as indicated. Immunoblot results are from a representative experiment performed in triplicate with β-
actin as loading control.
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of the overall levels of tyrosine phosphorylation of FAK
(p-FAK) (Figure 2B and 2C), whereas same treatment for
8 h caused more dramatic reduction of pY397FAK (~80%
reduction; Figure 6). These suggest that pY397FAK may be
a major target of TGZ treatment. The more dramatic inhi-
bition of pY397FAK than p-FAK was also observed previ-
ously in hypoxia-induced cytotrophoblast migration in
vitro [54].
The underlying mechanism of TGZ suppression of FAK
autophosphorylation remains unclear. pY397FAK levels
are increased by integrin clustering and FAK-Src kinases
association [9,12,13]. Decrease of pY397FAK levels by
TGZ may be exerted through interference with the interac-
tion between FAK and its activating molecules. In addi-
tion, FAK activity is regulated by protein-tyrosine
phosphatases (PTPs)-mediated dephosphorylation. FAK
is dephosphorylated by several PTPs such as SH2-contain-
ing tyrosine phosphatase 2 (SHP2) and low molecular
weight tyrosine phosphatase (LMW-PTP) or PTEN
[34,35,55-57]. These are candidate mediators of the TGZ
effect. The mechanisms involved in the inhibition of FAK
autophosphorylation by TGZ will be important to iden-
tify in future research.
Among the PTPs, PTEN particularly interests us since
PTEN has been linked to regulation of cell migration
[36,37]. The activity of PTEN itself is under novel regula-
tion. It is widely accepted that the lipid phosphatase of
PTEN is activated with its dephosphorylation [38-40]. The
dephosphorylated PTEN is preferentially translocated to
the vicinity of its substrates in the cell membrane such as
pY397FAK [58]. The dephosphorylation of PTEN also
leads to its eventual degradation [47]. The activation of
PTEN by TGZ is suggested by several of our observations
including: 1) decrease in phosphorylated AKT, which
indicates activation of PTEN (Figure 7A); 2) dose-depend-
ent decrease in p-PTEN levels accompanied by decrease in
total PTEN (Figure 5C and 5D); and 3) PTEN membrane
translocation (Figure 7). These lead to the suggestion that
TGZ can suppress pY397FAK levels through PTEN activa-
tion. In addition, we suspect at least two mechanisms
involving TGZ regulation of pY397FAK, since at 10 µM,
TGZ treatment inhibited pY397FAK but not PTEN translo-
cation. Thus TGZ at 10–30 µM may affect FAK autophos-
TGZ changes the ratio of PTEN localized in cytosol and plasma membrane Figure 7
TGZ changes the ratio of PTEN localized in cytosol and plasma membrane. (A) ES-2 cells were treated with various 
concentrations of TGZ for 24 h. Cell membrane and cytosolic fractions were isolated as described in Materials and Methods 
and then subjected to SDS-PAGE and Western blot analysis. The result of one representative assay from two similar independ-
ent experiments is shown. (B) Effect of TGZ on the distribution of PTEN. ES-2 cells were plated on FN (10 µg/mL)-coated cov-
erslips and incubated in 10% FBS medium with 0.1% DMSO or 20 µM TGZ for 24 h. Cells were then double stained with 
paxillin (FITC) and PTEN (rhodamine). These results are representative of triplicate experiments.
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phorylation by blocking its interaction with activating
proteins. At higher than 10 µM, TGZ leads to increased
PTEN activity and to the further inhibition of pY397FAK
formation.
The mechanism of TGZ-induced PTEN dephosphoryla-
tion/activation in ES-2 cells remains unclear. The activity
of PTEN is regulated by casein kinase 2 (CK-2) and small
GTPase RhoA and its downstream effector, RhoA-associ-
ated kinase (Rock) [47,59]. Interestingly, inhibition of
CK-2 and PTEN activity by TGZ was recently observed in
endothelial cells [60]. The possible role of CK-2 and
RhoA/Rock on TGZ-caused PTEN dephosphorylation can
be tested experimentally and deserves further investiga-
tion.
Conclusion
TGZ treatment can impair spreading and migration of ES-
2 cells, an ovarian carcinoma cell line with known high
motility. We suggest that TGZ or its analogues may be new
drugs for the prevention and treatment of ovarian cancer.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
YPT and YCY conceived the study, participated in the
study design, and manuscript preparation. TCH and SLC
participated in the study design, performed data analysis,
aided in troubleshooting assays and drafted the manu-
script. TCH, HYL and JYW conducted all experiments in
this paper. All authors read and approved the final manu-
script.
Acknowledgements
We thank Ping-Chang Kuo and I-Pin Choung for technical support. This 
study was supported by grants from the National Science Council, Taiwan 
(NSC 95-2314-B-195-009-MY3, NSC 95-3112-B-195-001) and Mackay 
Memorial Hospital (MMH-E-96006).
References
1 . S h i h  I e M ,  K u r m a n  R J :  Ovarian tumorigenesis: a proposed
model based on morphological and molecular genetic analy-
sis.  Am J Pathol 2004, 164:1511-1518.
2. Hu XF, Xing PX: Discovery and validation of new molecular
targets for ovarian cancer.  Curr Opin Mol Ther 2003, 5:625-630.
3. Ozols RF: Optimum chemotherapy for ovarian cancer.  Int J
Gynecol Cancer 2000, 10:33-37.
4. Thulesius HO, Lindgren AC, Olsson HL, Hakansson A: Diagnosis
and prognosis of breast and ovarian cancer: a population-
based study of 234 women.  Acta Oncol 2004, 43:175-181.
5. Schlaepfer DD, Mitra SK, Ilic D: Control of motile and invasive
cell phenotypes by focal adhesion kinase.  Biochim Biophys Acta
2004, 1692:77-102.
6. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG,
Frame MC: The role of focal-adhesion kinase in cancer – a new
therapeutic opportunity.  Nat Rev Cancer 2005, 5:505-515.
7. Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons
JT:  pp125FAK a structurally distinctive protein-tyrosine
kinase associated with focal adhesions.  Proc Natl Acad Sci USA
1992, 89:5192-5196.
8. Schaller MD: Biochemical signals and biological responses elic-
ited by the focal adhesion kinase.  Biochim Biophys Acta 2001,
1540:1-21.
9. Wozniak MA, Modzelewska K, Kwong L, Keely PJ: Focal adhesion
regulation of cell behavior.  Biochim Biophys Acta 2004,
1692:103-119.
10. Judson PL, He X, Cance WG, Van LL: Overexpression of focal
adhesion kinase a protein tyrosine kinase in ovarian carci-
noma.  Cancer 1999, 86:1551-1556.
11. Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gru-
man LM, Gershenson DM, Schaller MD, Hendrix MJ: Biological sig-
nificance of focal adhesion kinase in ovarian cancer: role in
migration and invasion.  Am J Pathol 2004, 165:1087-1095.
12. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons
JT:  Autophosphorylation of the focal adhesion kinase
pp125FAK directs SH2-dependent binding of pp60src.  Mol
Cell Biol 1994, 14:1680-1688.
13. Calalb MB, Polte TR, Hanks SK: Tyrosine phosphorylation of
focal adhesion kinase at sites in the catalytic domain regu-
lates kinase activity: a role for Src family kinases.  Mol Cell Biol
1995, 15:954-963.
14. Franco SJ, Rodgers MA, Perrin BJ, Han J, Bennin DA, Critchley DR: A
Huttenlocher Calpain-mediated proteolysis of talin regu-
lates adhesion dynamics.  Nat Cell Biol 2004, 6:977-983.
15. Aronsohn MS, Brown HM, Hauptman G, Kornberg LJ: Expression of
focal adhesion kinase and phosphorylated focal adhesion
kinase in squamous cell carcinoma of the larynx.  Laryngoscope
2003, 113:1944-1948.
16. Moon HS, Park WI, Choi EA, Chung HW, Kim SC: The expression
and tyrosine phosphorylation of E-cadherin/catenin adhesion
complex and focal adhesion kinase in invasive cervical carci-
nomas.  Int J Gynecol Cancer 2003, 13:640-646.
17. Recher C, Ysebaert L, Beyne-Rauzy LO, Mansat-De MV, Ruidavets JB,
Cariven P, Demur C, Payrastre B, Laurent G, Racaud-Sultan C:
Expression of focal adhesion kinase in acute myeloid leuke-
mia is associated with enhanced blast migration increased
cellularity and poor prognosis.  Cancer Res 2004, 64:3191-3197.
18. Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U, Bar-Shavit
R: Differential expression of protease activated receptor 1
(Par1) and pY397FAK in benign and malignant human ovar-
ian tissue samples.  Int J Cancer 2005, 113:372-378.
19. Issemann I, Green S: Activation of a member of the steroid hor-
mone receptor superfamily by peroxisome proliferators.
Nature 1990, 347:645-660.
20. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R,
Rosenfeld MG, Willson TM, Glass CK, Milburn MV: Ligand binding
and co-activator assembly of the peroxisome proliferator-
activated receptor-gamma.  Nature 1998, 395(6698):137-143.
21. Weng JR, Chen CY, Pinzone JJ, Ringel MD, Chen CS: Beyond per-
oxisome proliferator-activated receptor gamma signaling:
the multi-facets of the antitumor effect of thiazolidinedi-
ones.  Endocr Relat Cancer 2006, 13:401-413.
22. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of
insulin resistance and type II diabetes.  Diabetes 1996,
45:1661-1669.
23. Panigrahy D, Shen LQ, Kieran MW: A Kaipainen Therapeutic
potential of thiazolidinediones as anticancer agents.  Expert
Opin Investig Drugs 2003, 12:1925-1937.
24. Giannini S, Serio M, Galli A: Pleiotropic effects of thiazolidinedi-
ones: taking a look beyond antidiabetic activity.  J Endocrinol
Invest 2004, 27:982-991.
25. Masuda T, Wada K, Nakajima A, Okura M, Kudo C, Kadowaki T,
Kogo M, Kamisaki Y: Critical role of peroxisome proliferator-
activated receptor gamma on anoikis and invasion of squa-
mous cell carcinoma.  Clin Cancer Res 2005, 11:4012-4021.
26. Schaefer KL, Wada K, Takahashi H, Matsuhashi N, Ohnishi S, Wolfe
MM, Turner JR, Nakajima A, Borkan SC, Saubermann LJ: Peroxi-
some proliferator-activated receptor gamma inhibition pre-
vents adhesion to the extracellular matrix and induces
anoikis in hepatocellular carcinoma cells.  Cancer Res 2005,
65:2251-2259.
27. Chen Y, Wang SM, Wu JC, Huang SH: Effects of PPARgamma
agonists on cell survival and focal adhesions in a Chinese thy-
roid carcinoma cell line.  J Cell Biochem 2006, 98:1021-1035.BMC Cancer 2007, 7:216 http://www.biomedcentral.com/1471-2407/7/216
Page 12 of 12
(page number not for citation purposes)
28. Motomura W, Nagamine M, Tanno S, Sawamukai M, Takahashi N,
Kohgo Y, Okumura T: Inhibition of cell invasion and morpho-
logical change by troglitazone in human pancreatic cancer
cells.  J Gastroenterol 2004, 39:461-468.
29. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T: Ligands for
peroxisome proliferator-activated receptor gamma inhibit
growth and induce apoptosis of human papillary thyroid car-
cinoma cells.  J Clin Endocrinol Metab 2001, 86:2170-2177.
30. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen
EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, Fletcher JA, Hlatky L,
Hahnfeldt P, Folkman J, Kaipainen A: PPARgamma ligandsinhibit
primary tumor growth and metastasis by inhibiting angio-
genesis.  J Clin Invest 2002, 110:923-932.
31. Galli A, Ceni E, Crabb DW, Mello T, Salzano R, Grappone C, Milani
S, Surrenti E, Surrenti C, Casini A: Antidiabetic thiazolidinedi-
ones inhibit invasiveness of pancreatic cancer cells via PPAR-
gamma independent mechanisms.  Gut 2004, 53:1688-1697.
32. Liu J, Lu H, Huang R, Lin D, Wu X, Lin Q, Wu X, Zheng J, Pan X, Peng
J, Song Y, Zhang M, Hou M, Chen F: Peroxisome proliferator acti-
vated receptor-gamma ligands induced cell growth inhibi-
tion and its influence on matrix metalloproteinase activity in
human myeloid leukemia cells.  Cancer Chemother Pharmacol
2005, 56:400-408.
33. Sawai H, Liu J, Reber HA, Hines OJ, Eibl G: Activation of peroxi-
some proliferator-activated receptor-gamma decreases
pancreatic cancer cell invasion through modulation of the
plasminogen activator system.  Mol Cancer Res 2006, 4:159-167.
34. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis
C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M,
Tycko B, Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative
protein tyrosine phosphatase gene mutated in human brain
breast and prostate cancer.  Science 1997, 275:1943-1947.
35. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Lang-
ford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund
B, Teng DH, Tavtigian SV: Identification of a candidate tumour
suppressor gene MMAC1 at chromosome 10q233 that is
mutated in multiple advanced cancers.  Nat Genet 1997,
15:356-362.
36. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM: Inhi-
bition of cell migration spreading and focal adhesions by
tumor suppressor PTEN.  Science 1998, 280:1614-1617.
37. Tamura M, Gu J, Takino T, Yamada KM: Tumor suppressor PTEN
inhibition of cell invasion migration and growth: differential
involvement of focal adhesion kinase and p130Cas.  Cancer Res
1999, 59:442-449.
38. Lee JO, Yang H, Georgescu MM, Cristofano A, Maehama T, Shi Y,
Dixon JE, Pandolfi P, Pavletich NP: Crystal structure of the PTEN
tumor suppressor: implications for its phosphoinositide
phosphatase activity and membrane association.  Cell 1999,
99:323-334.
39. Georgescu MM, Kirsch KH, Kaloudis P, Yang H, Pavletich NP,
Hanafusa H: Stabilization and productive positioning roles of
the C2 domain of PTEN tumor suppressor.  Cancer Res 2000,
60:7033-7038.
40. Das S, Dixon JE, Cho W: Membrane-binding and activation
mechanism of PTEN.  Proc Natl Acad Sci USA 2003, 100:7491-7496.
41. Vazquez F, Sellers WR: The PTEN tumor suppressor protein:
an antagonist of phosphoinositide 3-kinase signaling.  Biochim
Biophys Acta 2000, 1470:M21-35.
42. Han S, Roman J: Rosiglitazone suppresses human lung carci-
noma cell growth through PPARgamma-dependent and
PPARgamma-independent signal pathways.  Mol Cancer Ther
2006, 5:430-437.
43. Teresi RE, Shaiu CW, Chen CS, Chatterjee VK, Waite KA, Eng C:
Increased PTEN expression due to transcriptional activation
of PPARgamma by Lovastatin and Rosiglitazone.  Int J Cancer
2006, 118:2390-2398.
44. Zhang W, Wu N, Li Z, Wang L, Jin J, Zha XL: PPAR gamma acti-
vator rosiglitazone inhibits cell migration via upregulation of
PTEN in human hepatocarcinoma cell line BEL-7404.  Cancer
Biol Ther 2006, 5:1008-1014.
45. Pfaff M, Jurdic P: Podosomes in osteoclast-like cells: structural
analysis and cooperative roles of paxillin proline-rich tyro-
sine kinase 2 (Pyk2) and integrin alphaVbeta3.  J Cell Sci 2001,
114:2775-2786.
46. Liu Y, Zhu Y, Rannou F, Lee TS, Formentin K, Zeng L, Yuan X, Wang
N, Chien S, Forman BM, Shyy JY: Laminar flow activates peroxi-
some proliferator-activated receptor-gamma in vascular
endothelial cells.  Circulation 2004, 110:1128-1133.
47. Torres J, Pulido R: The tumor suppressor PTEN is phosphor-
ylated by the protein kinase CK2 at its C terminus Implica-
tions for PTEN stability to proteasome-mediated
degradation.  J Biol Chem 2001, 276:993-998.
48. Yang YC, Tsao YP, Ho TC, Choung IP: Peroxisome proliferator-
activated receptor-gamma agonists cause growth arrest and
apoptosis in human ovarian carcinoma cell lines.  Int J Gynecol
Cancer 2007, 17:418-425.
49. Kokenyesi R, Murray KP, Benshushan A, Huntley ED, Kao MS: Inva-
sion of interstitial matrix by a novel cell line from primary
peritoneal carcinosarcoma and by established ovarian carci-
noma cell lines: role of cell-matrix adhesion molecules pro-
teinases and E-cadherin expression.  Gynecol Oncol 2003,
89:60-72.
50. Kohn EC, Travers LA, Kassis J, Broome U, Klominek J: Malignant
effusions are sources of fibronectin and other promigratory
and proinvasive components.  Diagn Cytopathol 2005, 33:300-308.
51. Casey RC, Skubitz AP: CD44 and beta1 integrins mediate ovar-
ian carcinoma cell migration toward extracellular matrix
proteins.  Clin Exp Metastasis 2000, 18:67-75.
52. Rieppi M, Vergani V, Gatto C, Zanetta G, Allavena P, Taraboletti G,
Giavazzi R: Mesothelial cells induce the motility of human
ovarian carcinoma cells.  Int J Cancer 1999, 80:303-307.
53. Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW: Thia-
zolidenediones mediate apoptosis in prostate cancer cells in
part through inhibition of Bcl-xL/Bcl-2 functions independ-
ently of PPARgamma.  Cancer Res 2005, 65:1561-1569.
54. Ilic D, Genbacev O, Jin F, Caceres E, Almeida EA, Bellingard-
Dubouchaud V, Schaefer EM, Damsky CH, Fisher SJ: Plasma mem-
brane-associated pY397FAK is a marker of cytotrophoblast
invasion in vivo and in vitro.  Am J Pathol 2001, 159:93-108.
55. Yu DH, Qu CK, Henegariu O, Lu X, Feng GS: Protein-tyrosine
phosphatase Shp-2 regulates cell spreading migration and
focal adhesion.  J Biol Chem 1998, 273:21125-21131.
56. von Wichert G, Haimovich B, Feng GS, Sheetz MP: Force-depend-
ent integrin- cytoskeleton linkage formation requires down-
regulation of focal complex dynamics by Shp2.  EMBO J 2003,
22:5023-5035.
57. Chiarugi P, Pani G, Giannoni E, Taddei L, Colavitti R, Raugei G,
Symons M, Borrello S, Galeotti T, Ramponi G: Reactive oxygen
species as essential mediators of cell adhesion: the oxidative
inhibition of a FAK tyrosine phosphatase is required for cell
adhesion.  J Cell Biol 2003, 161:933-944.
58. Tamura M, Gu J, Danen EH, Takino T, Miyamoto S, Yamada KM:
PTEN interactions with focal adhesion kinase and suppres-
sion of the extracellular matrix-dependent phosphatidyli-
nositol 3-kinase/Akt cell survival pathway.  J Biol Chem 1999,
274:20693-20703.
59. Li Z, Dong X, Wang Z, Liu W, Deng N, Ding Y, Tang L, Hla T, Zeng
R, Li L, Wu D: Regulation of PTEN by Rho small GTPases.  Nat
Cell Biol 2005, 7:399-404.
60. Lee KS, Park JH, Lee S, Lim HJ, Jang Y, Park HY: Troglitazone inhib-
its endothelial cell proliferation through suppression of
casein kinase 2 activity.  Biochem Biophys Res Commun 2006,
346:83-8.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/7/216/pre
pub